ArticleBulletin of experimental biology and medicine2025
Expression of the Extracellular Domain of the Thyrotropin Receptor Based on mRNA Isolated from Thyroid Tissue and Whole Blood of Patients with Toxic Diffuse Goiter (Graves' Disease).
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expression of the Thyroglobulin ChEL Domain in Whole Blood of Patients with Thyroid Pathology.Bulletin of experimental biology and medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fragments of the thyrotropin receptor gene (TSHR) encoding 432- and 389-bp regions of the extracellular domain corresponding to the autoantibody binding sites in autoimmune diseases of the thyroid gland (Graves' disease and Hashimoto's thyroiditis, respectively) were cloned based on mRNA isolated not only from the thyroid tissue, but also from the whole blood of patients with toxic diffuse goiter (Graves' disease). In a group of 18 patients, the 432-bp fragment was detected in 6 patients and the 389-bp fragment was detected in 3 patients. In one patient, both fragments were isolated from the blood. The results indicate that TSHR is expressed in the blood in 30% of patients with Graves' disease.
Indexed as
Identifiers
40153161What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.